Systems Pharmacology Dissection of Multi-Scale Mechanisms of Action of Formula for the Treatment of Gastrointestinal Diseases
Overview
Affiliations
Multi-components Traditional Chinese Medicine (TCM) treats various complex diseases (multi-etiologies and multi-symptoms) via herbs interactions to exert curative efficacy with less adverse effects. However, the ancient Chinese compatibility theory of herbs formula still remains ambiguous. Presently, this combination principle is dissected through a systems pharmacology study on the mechanism of action of a representative TCM formula, (HXZQ) prescription, on the treatment of functional dyspepsia (FD), a chronic or recurrent clinical disorder of digestive system, as typical gastrointestinal (GI) diseases which burden human physical and mental health heavily and widely. In approach, a systems pharmacology platform which incorporates the pharmacokinetic and pharmaco-dynamics evaluation, target fishing and network pharmacological analyses is employed. As a result, 132 chemicals and 48 proteins are identified as active compounds and FD-related targets, and the mechanism of HXZQ formula for the treatment of GI diseases is based on its three function modules of anti-inflammation, immune protection and gastrointestinal motility regulation mainly through four, i.e., PIK-AKT, JAK-STAT, Toll-like as well as Calcium signaling pathways. In addition, HXZQ formula conforms to the ancient compatibility rule of "" due to the different, while cooperative roles that herbs possess, specifically, the direct FD curative effects of (serving as drug), the anti-bacterial efficacy and major accompanying symptoms-reliving bioactivities of and (as ), the detoxication and ADME regulation capacities of (as ), as well as the minor symptoms-treating efficacy of the rest 7 herbs (as ). This work not only provides an insight of the therapeutic mechanism of TCMs on treating GI diseases from a multi-scale perspective, but also may offer an efficient way for drug discovery and development from herbal medicine as complementary drugs.
Wu Z, Yao L, Guo J, Xu Z, Wang Z Open Life Sci. 2024; 19(1):20220964.
PMID: 39655192 PMC: 11627061. DOI: 10.1515/biol-2022-0964.
Zhu Y, Ouyang H, Lv Z, Yao G, Ge M, Cao X Front Pharmacol. 2024; 15:1293464.
PMID: 38841366 PMC: 11150675. DOI: 10.3389/fphar.2024.1293464.
Li P, Wang D, Yang X, Liu C, Li X, Zhang X Molecules. 2024; 29(8).
PMID: 38675723 PMC: 11054111. DOI: 10.3390/molecules29081901.
Gasmi A, Noor S, Dadar M, Semenova Y, Menzel A, Benahmed A Curr Pharm Des. 2024; 30(14):1060-1074.
PMID: 38523518 DOI: 10.2174/0113816128217263240220060252.
Ouyang P, Kang D, You W, Shen X, Mo X, Liu Y Front Nutr. 2024; 11:1303002.
PMID: 38419848 PMC: 10899464. DOI: 10.3389/fnut.2024.1303002.